Stonegate Investment Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$9.32M Buy
40,253
+222
+0.6% +$45.2K 0.22% 59
2025
Q2
$7.43M Buy
40,031
+1,790
+5% +$333K 0.19% 59
2025
Q1
$8.01M Buy
38,241
+588
+2% +$114K 0.21% 55
2024
Q4
$6.69M Buy
37,653
+3,996
+12% +$735K 0.18% 60
2024
Q3
$6.65M Buy
33,657
+857
+3% +$160K 0.18% 60
2024
Q2
$5.63M Buy
32,800
+1,682
+5% +$279K 0.16% 61
2024
Q1
$5.67M Sell
31,118
-358,321
-92% -$61.8M 0.18% 67
2023
Q4
$60.4M Buy
389,439
+22
+0% +$3.21K 2% 16
2023
Q3
$58M Sell
389,417
-209
-0.1% -$30.7K 2.11% 17
2023
Q2
$52.5M Buy
389,626
+648
+0.2% +$95K 1.87% 17
2023
Q1
$62M Buy
388,978
+10,718
+3% +$1.64M 2.33% 14
2022
Q4
$61.1M Sell
378,260
-808
-0.2% -$124K 2.64% 13
2022
Q3
$50.9M Buy
379,068
+2,300
+0.6% +$330K 2.33% 14
2022
Q2
$57.7M Buy
376,768
+10,815
+3% +$1.65M 2.53% 11
2022
Q1
$59.3M Buy
365,953
+7,973
+2% +$1.16M 1.95% 14
2021
Q4
$48.5M Buy
+357,980
New +$42.3M 2.03% 13

Other funds holding ABBV

Stonegate Investment Group's ABBV Position: Q3 2025 in Review

Stonegate Investment Group increased its AbbVie (ABBV) stake by 0.55% in Q3 2025, buying an estimated $45.2K and bringing the position to 40,253 shares worth $9.32M. The position accounts for 0.22% of the portfolio, ranked #59.

Stonegate Investment Group first reported a position in ABBV in Q4 2021 and has held it in 16 quarters since. The position peaked at $62M in Q1 2023. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Stonegate Investment Group held 40,253 shares of AbbVie worth $9.32M as of Q3 2025.
  • Stonegate Investment Group bought 222 AbbVie shares in Q3 2025, an estimated $45.2K.
  • AbbVie made up 0.22% of Stonegate Investment Group's portfolio in Q3 2025, its #59 holding.
  • Stonegate Investment Group first reported a position in AbbVie in Q4 2021 and has held it in 16 quarters since.
  • Stonegate Investment Group's AbbVie position peaked at $62M in Q1 2023.
  • 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Stonegate Investment Group's 13F filing for Q3 2025, filed 3 Nov 2025.